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Summary
Background: The prevalence of chronic liver disease in women of child bearing age is 
increasing, leading to a higher incidence of pregnancy in this cohort. Chronic medical 
conditions have a significant adverse effect on maternal morbidity and mortality. To 
date, reviews on this topic have been written either from a hepatology or obstet-
rics viewpoint, and no specific guidelines are available solely for the management of 
chronic liver disease in pregnancy.
Aims: To produce a comprehensive review on the clinical management of women 
with chronic liver disease during pregnancy, addressing the risks of pregnancy to 
mother and child, how these risks can be ameliorated, and what additional considera-
tions are required for management of chronic liver disease in pregnancy.
Methods: Data were collected up to May 2020 from the biomedical database 
PubMed, national and international guidelines in gastroenterology and hepatology.
Results: During pregnancy, women with cirrhosis are more likely to develop decom-
pensated disease, worsening of portal hypertension, and to deliver premature infants.
Conclusions: The risks associated with pregnancy can be ameliorated by advanced 
planning, assessing risk using the model for end stage liver disease score and risk 
reduction through varices screening. A multidisciplinary approach is paramount in 
order to minimise complications and maximise the chance of a safe pregnancy and 
birth for mother and baby.
     |  421FAULKES Et AL.
1  | INTRODUC TION
Pregnancy in the presence of cirrhosis, defined as permanent scar-
ring of the liver, was considered a rare event. However, the epide-
miology of chronic liver disease in the Western world is changing. 
Liver disease and cirrhosis in adolescence and early adulthood are 
increasing, particularly amongst young women, with an incidence of 
46.9/100 000.1 As a result, pregnancy in the presence of cirrhosis is 
becoming more common.2,3
In the United Kingdom, the impact of chronic medical condi-
tions on maternal health is evaluated nationally by MBRRACE UK. 
All deaths that have occurred during pregnancy and up to a year 
post-partum are reviewed, either direct maternal deaths related 
to pregnancy, or indirect maternal deaths arising from pre-existing 
conditions or de novo disease presenting during pregnancy, but not 
directly attributable to it. Between 2011 and 2017, two thirds of all 
maternal deaths were in women with pre-existing medical condi-
tions. There was no improvement in the indirect maternal death rate 
during this period.4 As recommended by the national maternal mor-
tality confidential enquiries, active involvement of physicians and 
obstetricians before, during and following pregnancy in women with 
chronic medical conditions is vital if maternal morbidity and mor-
tality are to be improved. It must be recognised that many of these 
women will be unaware of the risks of pregnancy, and it is the duty 
of their physicians to ensure they are well informed.
For women with liver disease, the principle risks during pregnancy 
relate to heightened portal hypertension leading to decompensation; 
to the foetus, the risks are of prematurity, low birth weight and con-
siderations of medication exposure in utero. This article will discuss 
these risks and focus on the management of pre-existing chronic liver 
disease in pregnancy, rather than pregnancy-specific liver conditions.
2  | C ARDIOVA SCUL AR CHANGES IN 
PREGNANCY
During pregnancy the maternal cardiovascular system undergoes 
dramatic change, inducing a hyperdynamic circulation. Systemic 
vascular resistance decreases while venous return, heart rate and 
stroke volume increase.5 As a result, cardiac output increases by up 
to 30%-40% in the early third trimester.6-8 Activation of the renin-
angiotensin-aldosterone axis leads to fluid retention; plasma volume 
expands by 45% in the third trimester.9
As pregnancy progresses the gravid uterus compresses the inferior 
vena cava, and in late pregnancy can cause complete occlusion of the 
abdominal vena cava in a supine position. Collateral vessels expand to 
facilitate venous drainage during pregnancy, including the azygos and 
vertebral veins, and potentially the portal venous system.10,11
While measurements of portal and hepatic vein flow in preg-
nancy have historically produced conflicting results, more recent 
data using Doppler ultrasound have shown an increase in portal vein 
flow by 50% in late pregnancy with a corresponding increase in total 
liver blood flow.12-14 The clinical implications of these cardiovascular 
changes for women with pre-existing liver disease will be discussed 
below (Figure 1).
3  | BIOCHEMIC AL CHANGES IN 
PREGNANCY
Increased plasma volume creates a relative normocytic anaemia due 
to haemodilution.15 The platelet count also falls to the lower end 
of normal. Ten percent of women may develop a benign gestational 
thrombocytopenia in the second or third trimester, with platelet 
counts between 100 and 150 × 109 cells/L. Lower or rapidly falling 
platelet counts should prompt further investigation.16 Pregnancy is a 
hypercoagulable state, but INR and PT are not affected.15
While the reference ranges for most serum liver parameters re-
main similar in pregnancy, alkaline phosphatase and alpha-fetopro-
tein (AFP) are both higher, due to secretion from the placenta and 
foetal skeleton, and foetal liver, respectively. AFP increases with 
gestation and is affected by numerous factors including maternal 
weight, smoking and ethnicity, hence interpretation during preg-
nancy is difficult.17 A high result should be repeated in 1-2 weeks, and 
if rising greatly, further investigation may be warranted. Biochemical 
changes during pregnancy are summarised in Table 1.18,19
4  | FERTILIT Y IN CHRONIC LIVER DISE A SE
To some degree fertility rates are affected by the aetiology of liver 
disease and the presence or absence of cirrhosis. Women with 
autoimmune disease such as primary sclerosing cholangitis have 
conception rates equal with the general population.20 However, fer-
tility in women with established cirrhosis of any aetiology has his-
torically been low due to a combination of hypothalamic-pituitary 
dysfunction and low BMI resulting in amenorrhoea, reduced libido 
associated with chronic disease and, perhaps, reluctance from the 
medical profession to expose them to the risks associated with preg-
nancy.21 As the prevalence of cirrhosis in women of child bearing 
age increases, so too does the incidence of pregnancy in this co-
hort. Delivery rates in women with cirrhosis nearly doubled over a 
20-year period, and therefore it should not be assumed that these 
patients cannot conceive.3
As with many chronic conditions, the chances of a successful 
pregnancy are highest if the liver disease is well controlled, and mater-
nal risk factors minimised, before conception. It is also important that 
women feel supported in their pregnancy decisions and fully informed 
of the risks and help available before embarking on pregnancy.
5  | PRECONCEPTION COUNSELLING
All women with chronic liver disease should be asked about their fam-
ily plans. Those who wish to avoid pregnancy should be counselled 
regarding contraception. Long acting methods of contraception such 
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as intra-uterine devices are recommended due to their lower failure 
rate, but barrier methods, copper devices and progestin or combined 
hormone contraceptives may all be offered to women with chronic 
liver disease and compensated cirrhosis. The combined oral contra-
ceptive pill is contraindicated in decompensated cirrhosis.22
For those wishing to explore the option of pregnancy, counsel-
ling should be delivered by a team with experience in managing liver 
disease in pregnancy. Ideally this would include a gastroenterologist 
or hepatologist, obstetrician, dietician, specialist nurse and mid-
wife, with communication to the primary care physician.
Assessment by a dietician and optimisation of the woman’s nutri-
tional status is an important facet of multidisciplinary team manage-
ment. Women should be advised to take 400 µm of folic acid daily 
prior to conception and throughout the first trimester to prevent 
neural tube defects. Higher doses of 5mg daily are recommended 
for women with a BMI >30.23,24
F I G U R E  1   Normal physiological 
changes in pregnancy. Created 
with BioRender.com


























GGT (IU/L) ↔ 7-33 3-43






Albumin (g/L) ↓ 35-46 28-37
Platelet (109/L) ↔ 150-400 150-400




Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl 
transpeptidase; alk phos, alkaline phosphatase; INR, international normalised ratio; and PT, 
prothrombin time.
TA B L E  1   Physiological differences in 
serum biochemistry during pregnancy. 
Note that reference ranges will vary 
locally.18,19
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Prior to conception, women with cirrhosis should be up to date with 
endoscopic variceal surveillance, according to Baveno criteria.25 Varices 
should be treated with beta blockers or band ligation. While beta block-
ers do confer a risk of intra-uterine growth restriction (IUGR), foetal and 
neonatal bradycardia and neonatal hypoglycaemia, benefits are deemed 
to outweigh these risks.26 The Food and Drug Administration (FDA) 
and American Society of Gastroenterology both advocate the use of 
propranolol during pregnancy for primary prophylaxis against variceal 
haemorrhage.27 Risks associated with beta blockers are a class effect, 
therefore carvedilol and nadolol may also be used.
Due to the cardiovascular changes in pregnancy discussed 
above, all women with portal hypertension should have a further 
screening endoscopy in the second trimester.27 Endoscopists 
should be mindful of the increased risk of aspiration of gastric con-
tents in the pregnant patient. Potential risks to the foetus can arise 
from medication use and maternal hypotension; therefore, normal 
blood pressure should be maintained during the procedure.28 Low 
dose midazolam may be administered, with judicious use in late 
pregnancy as high dose benzodiazepines can cause respiratory de-
pression in the neonate.29 Gastroscopy should be performed in the 
left lateral position to minimise compression of the inferior vena 
cava by the gravid uterus and so reduce the risk of maternal hypo-
tension, decreased uterine flow and foetal hypoxia.27 Endoscopy 
in pregnancy has been associated with prematurity and low birth 
weight infants, but not with congenital malformation or stillbirth.30 
Overall, the risks are outweighed by the significant benefit of 
screening and treating varices, and endoscopy performed by an ex-
perienced clinician is usually safe in pregnancy (Table 2).
6  | MATERNAL RISKS
The principle risks to the mother arise from decompensation of liver 
disease during pregnancy, which may affect 10%-16% of women.31,32 
Evaluating this risk been reported using Model for End stage Liver 
Disease (MELD). This score incorporates serum creatinine, bilirubin 
and INR, and was first used to predict the mortality risk for patients 
with cirrhosis undergoing a procedure.33 United Kingdom Model for 
End stage Liver Disease (UKELD) is a similar score that also includes 
serum sodium.34 Westbrook et al describe the use of MELD in preg-
nancy. Women with a MELD ≤6 did not suffer any complications. 
Those who decompensated during pregnancy all had a MELD score 
≥10. It is this score of severity, rather than the aetiology of liver dis-
ease, that correlates most closely with pregnancy outcome.31
Maternal mortality in cirrhosis is between 0% and 4%.3,31,32,35 
While this has improved over recent decades, it remains significantly 
above the national maternal mortality rate (0.01%).4 Increased rates 
of placental abruption and post-partum haemorrhage have also been 
reported.3,36 The risks are summarised in Figure 2.
7  | FOETAL RISKS
Infants born to women with chronic liver disease are more likely to be 
premature and to have low birth weight. Prematurity may be seen in up 
to two thirds of cases, although the majority of these infants are born 
from 30 weeks onwards. Delivery at <30 weeks may occur in one in five 
pregnancies. Prematurity is associated with higher UKELD and MELD 
scores at conception, but not with the aetiology of liver disease.31
Rates of spontaneous abortion, defined as pregnancy loss before 
24 weeks gestation, are similar to the general population.31,37 There 
is no significant increased risk of stillbirth, miscarriage or congenital 
malformation.2,35,38
8  | MODE OF DELIVERY
Around the time of delivery, the risk of variceal haemorrhage in-
creases, either due to Valsalva manoeuvres during vaginal birth 
or inadvertent trauma to intra-abdominal varices during caesar-
ean section.27,39 There are no studies directly comparing the two 
modes of birth in women with chronic liver disease. Rates of cae-
sarean section are higher compared to the general population, but 
this may be due to clinician bias.3 In order to reduce the risk of 
variceal haemorrhage, a screening upper GI endoscopy should be 
performed in the second trimester (see above), and antenatal imag-
ing of the pelvis with MRI may help to identify pelvic varices and 
inform a delivery plan for obstetricians. In women whose varices 
have been treated and eradicated, no additional considerations for 
birth are necessary. If there are small varices present, vaginal birth 
is permissible but a short second stage of labour is advised. In the 
case of significant varices, elective caesarean section may be con-
sidered, but evidence guiding decisions on delivery for such women 
is scarce, and will therefore require a case by case approach.
9  | MANAGEMENT OF DECOMPENSATED 
CIRRHOSIS DURING PREGNANCY
9.1 | Varices
By 34 weeks gestation, the maternal circulating volume has expanded 
by up to 50%.15 The associated increase in portal venous flow and 
pressure augments the risk of variceal haemorrhage, making it the 
TA B L E  2   Summary of key points to address during pre-
pregnancy counselling
Pre-pregnancy counselling
Women with chronic liver disease can have a successful pregnancy
Chances of conception are greatest when the chronic disease is well 
controlled
MDT should include a gastroenterologist/hepatologist, obstetrician, 
specialist nurse, midwife, dietician and primary care physician
Screen for and treat oesophageal varices prior to conception
Beta blockers are recommended for primary prophylaxis against 
variceal haemorrhage
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most frequent and significant mode of hepatic decompensation dur-
ing pregnancy. The incidence of variceal bleed has been described 
to differing degrees. Recent case series report an incidence of 5% 
for all patients with cirrhosis, with a maternal mortality rate of 0%-
18%.3,31,40 Infants are more likely to have low birth weight if exposed 
to poorly controlled variceal haemorrhage while in utero.41
The risk of variceal haemorrhage is highest in the second trimes-
ter and labour.27 In the case of an acute bleed, immediate resusci-
tation with fluids and blood products and the use of antibiotics all 
remain appropriate in pregnancy. Terlipressin and octreotide can 
cause uterine vasoconstriction and ischaemia, but these risks must 
be weighed against the mortality benefit to the mother, and there-
fore may be required for life threatening haemorrhage.42,43
Upper GI endoscopy should be performed in the left lateral position, 
as discussed above. Successful placement of a TIPSS in pregnant women 
has been reported in cases where endoscopic therapy has failed.44 This 
involves placing a stent through the liver, between the portal vein and in-
ferior vena cava, under fluoroscopic guidance. Radiation exposure to the 
foetus can increase the risk of childhood leukaemia and congenital mal-
formation.45 Radiation sparing manoeuvres have been described during 
TIPSS that limited the estimated foetal radiation exposure to 5.49mSv, 
only slightly above annual background radiation of 3-4mSv.46
9.2 | Splenic artery aneurysm
While rare in the general population, aneurysms of the splenic artery 
are strongly associated with pregnancy.47 Increased splanchnic flow 
develops due to a hyperdynamic circulation and proximal shunting from 
the pressure of the gravid uterus.48 These effects are compounded in 
women with portal hypertension, and therefore the risk of developing 
splenic artery aneurysm (SAA) in pregnancy is even greater, although 
the incidence for this specific cohort is not known.49,50
Ruptured SAA’s usually present in the second or third trimes-
ter with acute abdominal pain and profound hypovolaemic shock. 
Mortality has historically been as high as 70%, although more re-
cently a rate of 21% has been reported.48,50 Management is with 
splenic artery ligation or splenectomy by emergency laparotomy. 
Rupture during labour is uncommon.47,48
Management of non-ruptured SAA is not well defined. Elective 
treatment has been recommended for aneurysms >2 cm. However, 
aneurysms as small as 0.5 cm have been shown to rupture during 
pregnancy, prompting some clinicians to advocate proactive manage-
ment of SAA of any size in a pregnant patient.47,48,51 As such, women 
with cirrhosis should be screened for SAA with ultrasound scan. 
Management may include aneurysm ligation or splenectomy for distal 
SAA’s. More recently, successful decompression of the portal system 
with TIPSS followed by embolisation of the splenic artery has been 
reported.49
9.3 | Ascites and spontaneous bacterial peritonitis
Ascites during pregnancy affects around 10% of women with cir-
rhosis.3,39 Diuretics such as furosemide and bumetanide can be 
used to control ascites.29 Spironolactone has been shown to cause 
F I G U R E  2   Pathological changes in 
pregnancy and chronic liver disease. 
Created with BioRender.com
Pathological changes in pregnancy













Complications of raised portal
pressure
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feminisation of the male foetus in animal models, but is permissible 
for use during pregnancy if the benefit is deemed sufficient.
Pregnancy is a relative contraindication to therapeutic paracen-
tesis, but may be necessary for refractory ascites.51 TIPSS is not rou-
tinely recommended during pregnancy, although there are isolated 
case reports of successful placement.44
Spontaneous bacterial peritonitis should be managed according 
to international guidelines with human albumin solution on Day 1 
and Day 3, along with third generation cephalosporins.52 Quinolones 
should be avoided in pregnancy.29
9.4 | Hepatic encephalopathy
Hepatic encephalopathy in pregnancy is rare, affecting 1%.3 
Precipitating factors should be sought, including infection, electro-
lyte disturbance, medications and GI haemorrhage. Lactulose is not 
known to be harmful. Rifaximin has been shown to cause birth de-
fects in animal models; the effect on the human foetus is not yet 
clear, and therefore it should be avoided in pregnancy.52
9.5 | Porto-pulmonary hypertension
This rare condition has not been reported in pregnancy. Pulmonary 
hypertension is considered a contraindication to pregnancy due to 
the risk of right ventricular failure and an unacceptably high maternal 
mortality rate. For the small cohort who become pregnant despite 
medical advice, management by a specialist team and planned elec-
tive delivery are crucial. Where pulmonary hypertension is well con-
trolled, maternal mortality has improved, yet at 12-33% it remains 
far above the national average (Table 3).53-55
10  | SPECIFIC CONDITIONS
10.1 | Hepatitis B
All pregnant women with chronic hepatitis B and advanced fibrosis or 
cirrhosis should be treated with tenofovir disoproxil (TDF). Women 
already established on a different antiviral should be switched to 
tenofovir at the earliest opportunity.56 All women should have LFT’s 
monitored during pregnancy. A monitoring interval of 6 weeks in the 
first and second trimester, and every 4 weeks in the final trimester 
has been suggested.57
The mode of delivery and its potential role in vertical transmis-
sion has been studied, but at present there is insufficient data to rec-
ommend caesarean over vaginal birth, and therefore both modes of 
delivery may be offered.58 Infants born to HBsAg positive mothers 
should receive hepatitis B immunoglobulin (HBIG) and vaccination 
within 12 hours of delivery, followed by two further vaccines at 1 
and 12 months. This is in addition to the routine vaccination pro-
gramme for all infants, which includes hepatitis B vaccines at 8, 12 
and 16 weeks. The combination of HBIG and vaccination reduces 
vertical transmission from over 90% to less than 10%.59
Women with high HBsAg levels (>4 log10 IU/ml) or Hep B DNA 
>200 000 IU/L are at high risk of transmission despite the use of 
HBIG and vaccination, and should therefore receive prophylactic 
tenofovir from the start of the third trimester to delivery. TDF may 
be continued up to 12 weeks post-partum at the discretion of the cli-
nician, and agreed with the patient. Breastfeeding is safe, including 
women taking tenofovir.57
Hepatitis B may flare post-partum, therefore, continuted moni-
toring of ALT and Hepatitis B DNA levels is necessary.60 Flares may 
relate to post-partum immunological changes in the mother, and 
can lead to HepBeAg seroconversion.61 ALT should be monitored 
monthly for 3 months post-partum, then at 6 and 12 months.58,62
10.2 | Hepatitis C
As hepatocellular damage and fibrosis in hepatitis C are largely im-
mune mediated, the relative immune paresis of pregnancy generally 
results in lower ALT and higher hepatitis C RNA in the second and third 
trimesters. Fibrosis is not advanced by pregnancy.63 The principle con-
cern pertains to vertical transmission of the virus, which for untreated 
women is around 6%.64 HIV co-infection has been shown to increase 
this risk, although it is lower for women established on treatment with 
low or undetectable HIV viral load.65,66 At present, treatment is not 
recommended during pregnancy due to insufficient data on the safety 
profile of direct acting antivirals on foetal development, although a 
couple of case series have reported treatment success with sofosbu-
vir ± ledipasvir without adverse outcome.67 Ribavirin is teratogenic 
and should be stopped at least 6 months prior to conception.68
Currently, the only strategies to reduce vertical transmission 
are to treat HIV and avoid invasive procedures during labour, such 
as foetal scalp monitoring or the use of forceps. It is, therefore, 
preferential for women complete antiviral treatment prior to con-
ception.68 All women should be offered HIV testing as part of their 
TA B L E  3   Summary of emergency management of 




chronic liver disease in 
pregnancy
Variceal haemorrhage: Resuscitate, 
endoscope in left lateral position, 
avoid terlipressin unless life 
threatening haemorrhage
Ascites: Spironolactone or furosemide 
if required, paracentesis if necessary
SBP: Give human albumin solution and 
antibiotics, avoid quinolones
Hepatic Encephalopathy: Investigate 
for precipitant. Use lactulose, avoid 
rifaximin
Ruptured Splenic Artery Aneurysm: 
Resuscitate, emergency laparotomy
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booking bloods. Hepatitis C screening in pregnancy is conducted in 
the United States, but not offered routinely in the United Kingdom.
If antiviral treatment is being considered after delivery, hepatitis 
C RNA should be tested again as spontaneous clearance of hepatitis 
C can occur post-partum.68 Women with hepatitis C can breastfeed, 
as long as nipples are not cracked or bleeding.69 Maternal antibodies 
can be transferred in utero so infant testing for hepatitis C should be 
delayed until 12 months of age.66,70
10.3 | Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease places women at greater risk of de-
veloping gestational diabetes, independent of body mass index (BMI), 
although screening is currently reserved for women with BMI >30 or 
other risk factors, not non-alcoholic fatty liver disease (NAFLD).71-75 
Increased rates of pre-eclampsia are also associated with NAFLD.72
The risk of complications for women with NAFLD will be influenced 
by the presence of co-morbidities associated with the metabolic pheno-
type. Obesity, hypertension and diabetes can each exert independent, 
adverse effects on pregnancy. Management of NAFLD in pregnancy 
may, therefore, require input from multiple medical specialties.
10.4 | Autoimmune hepatitis
Disease activity of autoimmune hepatitis (AIH) may increase during 
pregnancy, but for many women it will initially reduce and then flare 
post-partum.76 Immunosuppression in the form of prednisolone or 
azathioprine is safe in pregnancy and breastfeeding, and should be 
continued in order to maintain maternal, and therefore foetal, health. 
Mycophenolate is associated with congenital abnormalities and spon-
taneous abortion, and therefore alternative treatment should be used 
for women considering pregnancy. The MHRA advise a minimum 
washout period of 6 weeks between stopping treatment and concep-
tion.77 However, experienced hepatologists recommend discontinuing 
mycophenolate for 6 months, allowing time for introduction of alterna-
tive immunosuppression and disease stabilisation prior to pregnancy.42 
Women are more likely to have a healthy pregnancy and successful 
delivery if AIH has been well controlled for a year prior to conceiving.
Monitoring LFTs on a monthly basis is advised post-partum. 
Flares usually respond to increased immunosuppression. Women 
who reduce immunosuppression during pregnancy are more likely 
to flare after delivery, highlighting the importance of pre-pregnancy 
counselling and reassurance regarding the safety profile of specific 
medication during pregnancy.78
10.5 | Primary biliary cholangitis and primary 
sclerosing cholangitis
Pregnant women with primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) can expect to have similar outcomes to 
the general population.20,79 However, pruritis may be exacerbated 
due to worsening cholestasis. Symptom management may include 
ursodeoxycholic acid and second line therapy with cholestyramine, 
both of which are safe to use in pregnancy. Rifampicin may also be 
used, but it inhibits vitamin K production.80 Neonates born to women 
taking rifampicin are, therefore, at greater risk of vitamin K deficiency 
and bleeding, and so internationally recommended vitamin K supple-
mentation within 6 hours of delivery becomes particularly pertinent 
for these infants.81
10.6 | Wilson’s disease
Prior to conception, women with Wilson’s may wish to discuss the 
risks of disease transmission. Wilson’s is autosomal recessive, with 
a 0.5% risk of homozygosity in infants born to affected mothers. 
Genetic testing of the partner prior to conception will help clini-
cians inform families of the likelihood of having a child affected by 
Wilson’s.82
Women established on chelation therapy have significantly 
lower rates of spontaneous abortion than treatment naïve pa-
tients.83 Interruptions to treatment during pregnancy can lead to 
fulminant liver failure; therefore, consistent therapy throughout 
pregnancy is advised.84 Dose reduction of chelating agents by 25%-
50% is recommended, particularly during the third trimester, in order 
to promote wound healing in the case of caesarean delivery. No dose 
adjustment is required to zinc sulphate. Women taking penicillamine 
should avoid breastfeeding.82,85
10.7 | Non-cirrhotic portal hypertension
Women with non-cirrhotic portal hypertension (NCPH) have nor-
mal fertility, but are at risk of similar complications from portal hy-
pertension as those with cirrhosis. Variceal haemorrhage affects 
8%-34% of pregnancies, and is more likely if women are diagnosed 
with de novo disease during pregnancy. Worsening ascites may be 
seen in 0%-2%.86-88 Women are at risk of developing portal vein 
thrombosis. It may be appropriate to discuss the pros and cons of 
venous thromboembolism prophylaxis in women who are not al-
ready anticoagulated, particularly for 6 weeks post-partum, in order 
to reduce the risk of developing a portal vein thrombosis during this 
procoagulant period.87
Neonatal outcomes are generally good, although some studies 
report an association between NCPH and pre-term delivery (0%-
50%) and low birth weight infants.87,89
10.8 | Hepatocellular carcinoma
As hepatocellular carcinoma (HCC) incidence peaks in the 8th 
decade and is more common in men, it is extremely rare in preg-
nancy.90 Incidence is associated with higher parity.91 Although 
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oestrogens and pregnancy can accelerate the growth of hepatic 
adenomas, their effect on HCC is not clearly defined.92-94 Women 
may be asymptomatic or present with a palpable mass, or acute 
abdominal pain in the case of tumour rupture.95 Synthetic func-
tion is usually preserved and liver disease remains compensated.96 
HCC may be diagnosed by ultrasound and further characterised 
with non-contrast MRI. Alpha-fetoprotein is difficult to interpret 
in pregnancy as it is also produced by the foetal gut and liver, af-
fected by maternal characteristics, and is not secreted by all hepa-
tocellular tumours.97
Management during pregnancy may include hepatectomy.98,99 
Earlier diagnosis and active treatment have translated to modest im-
provements in survival for this small cohort.96
11  | CONCLUSIONS
The rising prevalence of cirrhosis in young women has led to in-
creased incidence of chronic liver disease in pregnancy. These 
women are at a higher risk of decompensated disease, variceal 
bleed and premature delivery, resulting in higher rates of low birth 
weight infants. The UK Obstetric Surveillance System (UKOSS) 
has conducted a national survey to better establish the incidence 
and outcomes of pregnancy in cirrhosis, the results of which are 
awaited with interest by the authors. Currently, assessment of risk 
using the MELD score, screening for oesophageal and pelvic varices 
and splenic artery aneurysm may ameliorate the complication rate. 
Women with chronic liver disease have improved outcomes if their 
disease is well controlled prior to conceiving, and monitored dur-
ing pregnancy. Multidisciplinary management is essential in order to 
continue to improve maternal morbidity and mortality for women 
with chronic liver disease.
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